Breaking News, Financial News

Merck 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck 2Q Revenues: $6.1 billion (+12%) 2Q Earnings: $1.7 billion (+6%) YTD Revenues: $11.9 billion (+6%) YTD Earnings: $3.4 billion (+12%) Comments: Led by Gardasil, vaccine sales reached $1.0 billion in 2Q, up from $349 million. Singular sales rose 15% to $1.1 billion. Combined Vytorin/Zetia sales were $1.3 billion. R&D costs dropped 12% to $1.0 billion for the quarter. Higher costs in 2Q2006 reflected R&D costs from the GlycoFi acquisition. FY2007 restructuring costs ar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters